PTC TherapeuticsPTCT
About: PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Employees: 939
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 6 (+3) [Q1 2025]
100% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 25
27% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $12.5M
15% more capital invested
Capital invested by funds: $3.51B [Q4 2024] → $4.02B (+$516M) [Q1 2025]
9% more funds holding
Funds holding: 238 [Q4 2024] → 260 (+22) [Q1 2025]
0.91% less ownership
Funds ownership: 100.76% [Q4 2024] → 99.86% (-0.91%) [Q1 2025]
8% less repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 93
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Wells Fargo Tiago Fauth | 44%upside $74 | Overweight Maintained | 27 May 2025 |
B of A Securities Tazeen Ahmad | 33%upside $68 | Buy Upgraded | 9 May 2025 |
Barclays Gena Wang | 18%downside $42 | Equal-Weight Maintained | 8 May 2025 |
Baird Joel Beatty | 29%upside $66 | Outperform Maintained | 7 May 2025 |
RBC Capital Brian Abrahams | 13%upside $58 | Outperform Maintained | 7 May 2025 |
Financial journalist opinion
Based on 26 articles about PTCT published over the past 30 days
